Immunotherapies and Other Provocative Clinical Topics Headline the Agenda for the 9th Annual Great Debates and Updates in Gastrointestinal Malignancies

Share Article

In the era of personalized medicine, more than 200 community oncologists will gather in New York City for this debate-style conference on GI Cancers

HMP, a leading healthcare event and education company today announced that Imedex, a wholly owned subsidiary of HMP, will hold its 9th annual Great Debates and Updates in Gastrointestinal Malignancies on March 23-24 at the Marriott Marquis in New York. Through a series of expert debates covering varied perspectives on emerging clinical topics, the two-day meeting will highlight the most recent developments in GI malignancies and offer participants the opportunity to engage in insightful discussions on the research and implications for community oncology practices.

Great Debates and Updates in Gastrointestinal Malignancies is a premier forum for community oncologists and other healthcare professionals involved in the therapeutic management of GI cancers. 2018 marks its ninth year, and is chaired by Axel Grothey, MD, Oncologist, Mayo Clinic and David H. Ilson, MD, PhD, Medical Oncologist, Memorial Sloan Kettering Cancer Center.

The scientific agenda will address immunotherapies, rare tumors, and colorectal, pancreatic, and hepatobiliary cancers.

“Through a provocative series of debates, the program will explore the expanding role of immunotherapy agents, the emergence of liquid biopsy technology, and the role of regional therapies and controversies in the management of oligometastatic disease” said David H. Ilson, MD, PhD, conference co-chair. “Internationally recognized investigators will challenge, educate, and stimulate new thinking in the era of genomic profiling and personalized medicine.”

The unique educational forum serves as an opportunity to bring the gastrointestinal oncology community together to debate, discuss and learn from experts and one another, to ultimately improve patient outcomes.

“Year after year, we seek out the biggest names in the GI cancer field to join our faculty. These experts discuss controversial topics and provide viewpoints and guidance on the issues oncologists face in their daily practice. Attendees will leave the conference better equipped to make informed decisions based on individual patient needs,” said Chris Bolwell, executive vice president, Imedex.

To learn more about the meeting or to register, visit greatdebatesingimalignancies.com.

About HMP
HMP is the force behind Healthcare Made Practical—and is a multichannel leader in healthcare events and education, with a mission to improve patient care. The company produces accredited medical education events and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include Consultant360, the monthly, award-winning digital platform relied upon by primary care providers; Psych Congress, the largest independent mental health meeting in the U.S.; the ESMO World Congress on Gastrointestinal Cancers; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP is supported by its lead investor, Susquehanna Growth Equity, LLC (SGE). For more information, visit hmpglobal.com.

About Imedex®
Imedex® an HMP company, is an industry leader in the creation of independent, accredited medical education for healthcare professionals that improves patient care around the world. With an emphasis in oncology, hematology, and gastroenterology, the company develops high-quality scientific programming that translates the latest research into clinically relevant information. Imedex provides more than 50,000 e-learning experiences annually and since 2001, its live conferences have welcomed more than 100,000 attendees.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kelly McCurdy
HMP
+1 610.560.0500 x4304 Ext: 4304
Email >
Follow us on
Visit website